For more than a decade, scientists have tested a group of cancer drugs known as BET inhibitors with high hopes. The science behind them seemed strong. Many tumors rely on oncogenes that are switched on with help from “Bromo- and Extra-Terminal domain” (BET) proteins, so blocking those proteins was expected to slow cancer growth. In laboratory experiments, that approach often worked. But in real patients, the results have been far less impressive, with modest benefits, notable side effects, and no reliable way to predict who might respond.
Now, researchers at the Max Planck Institute of Immunobiology and Epigenetics (MPI-IE) in Freiburg believe they have uncovered a key reason for this gap between theory and reality. Their findings also point toward a more precise way to design future treatments.
Rethinking BET Proteins as Drug Targets
BET inhibitors were designed to block a shared feature that all BET proteins use to attach to chromatin, the tightly packed structure of DNA and proteins where genes are stored and controlled. The idea was straightforward. If you stop these proteins from binding to chromatin, you can shut down the machinery that activates cancer-driving genes.
This strategy relied on a major assumption that all BET proteins behave similarly. New research from the lab of Asifa Akhtar suggests that assumption does not hold up. The study shows that two important BET proteins, BRD2 and BRD4, actually perform different tasks at separate stages of gene activation.
BRD4 is involved later in the process. It helps release RNA Polymerase II, the enzyme that drives genes into active transcription. Most current therapies focus on this step. In contrast, BRD2 works earlier, helping assemble and organize the molecular components needed to start transcription in the first place.
A Molecular “Stage Manager” Behind Gene Activation
Because BRD2 and BRD4 act at different points, blocking both at the same time, as many current drugs do, interferes with multiple steps of gene activation. This can lead to unpredictable and context-dependent effects.
“Think of gene activation like stage production. BRD2 sets up the stage: assembling the props, costumes and actors to ensure preparations run smoothly. BRD2 then gives BRD4, the actor, the “start” signal to begin with the performance,” says Asifa Akhtar, who led the study at the MPI-IE. “Previous studies had been focused almost entirely on the performance. Our data shows that the setup work happening before is just as critical for gene activation,” explains Asifa Akhtar.
For years, BRD2 was considered less important than BRD4. The new findings challenge that view. One reason is how BRD2 responds to signals within the cell. The enzyme MOF places chemical tags called histone acetylations onto chromatin. These marks act like a guidance system, indicating which genes should be activated and where BRD2 should begin its work.
BRD2 is especially sensitive to these “bookmarks.” When MOF is removed, BRD2 can no longer stay attached to chromatin, while other BET proteins remain largely unaffected. “The findings support a model in which acetylated chromatin creates a platform that allows regulatory proteins like BRD2 to concentrate and prepare the transcription machinery for when it will be needed,” says first author Umut Erdogdu from the Akhtar lab.
The Role of Clustering in Gene Control
In addition to recognizing these signals, BRD2 also helps organize the physical layout of the transcription machinery. It forms clusters at gene sites, bringing together the necessary components exactly where they are needed to begin transcription.
“To understand the importance of the clustering for gene transcription, we removed only the specific part of BRD2 responsible for forming clusters while leaving the rest of the protein intact,” explains Umut Erdogdu.
The outcome was dramatic. Even though BRD2 was still present in the nucleus, gene transcription slowed almost as much as when the entire protein was removed. “This demonstrates that clustering is not a side effect, but a functional feature of transcription regulation. And like a stage manager, BRD2 ensures that every performer and every piece of equipment is in place before the curtain rises,” says Asifa Akhtar.
Toward More Precise Cancer Therapies
These insights suggest a new direction for cancer drug development. Instead of broadly blocking all BET proteins through their shared chromatin-binding ability, future therapies could focus on the distinct roles of BRD2 and BRD4.
By targeting these proteins more selectively, researchers may be able to create treatments that are both more effective and more predictable. Understanding how each protein contributes to gene activation could help refine strategies that better match the biology of different cancers.
Key Takeaways
- Why some cancer drugs fall short: Researchers at the Max Planck Institute of Immunobiology and Epigenetics uncovered why BET inhibitors have not performed as well as hoped in clinical trials, despite strong early promise.
- Two proteins, two distinct jobs: The study reveals that BET proteins BRD2 and BRD4 play different roles in turning genes on. This crucial difference helps explain why targeting them together may not work as expected.
- A path to better treatments: Most current drugs block both proteins at once. The new findings suggest that more precise targeting of BRD2 and BRD4 could lead to more effective and predictable cancer therapies.